We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Importance of CD4+CD25+ly in UC1. Investigation of Difference Between Blood Concentration IL 17, IL 33, Regulatory T ly in Patients With UC and Control Group

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2008 by Clinical Hospital Center, Split.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00805428
First Posted: December 9, 2008
Last Update Posted: December 9, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Clinical Hospital Center, Split
  Purpose
Mucosal inflammation in patients with UC is the result of immunosuppression disturbance because decreasing number of regulatory T ly and activation IL 17

Condition
Ulcerative Colitis

Study Type: Observational
Study Design: Observational Model: Case Control

Resource links provided by NLM:


Further study details as provided by Clinical Hospital Center, Split:

Estimated Enrollment: 32
Study Start Date: September 2008
Groups/Cohorts
2
control group
patients with UC
patients with UC, without corticosteroid or immunosuppressive therapy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
patients with UC and control group
Criteria

Inclusion Criteria:

  • endoscopic confirmed diagnosis

Exclusion Criteria:

  • corticosteroid or immunosuppressive therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00805428


Contacts
Contact: Jasna Ajdukovic, MSc 0917983374 jasna.ajdukovic@gmail.com

Locations
Croatia
Klinički bolnički centar Split Recruiting
Split, Croatia
Contact: Jasna Ajdukovic, MSc    0917983374    jasna.ajdukovic@gmail.com   
Sponsors and Collaborators
Clinical Hospital Center, Split
  More Information

Responsible Party: Jasna Ajdukovic, General practice
ClinicalTrials.gov Identifier: NCT00805428     History of Changes
Other Study ID Numbers: UC
First Submitted: December 8, 2008
First Posted: December 9, 2008
Last Update Posted: December 9, 2008
Last Verified: December 2008

Additional relevant MeSH terms:
Colitis, Ulcerative
Colitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Inflammatory Bowel Diseases
Colonic Diseases
Intestinal Diseases